A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia ® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)
Condition: Postmenopausal Women With Osteoporosis Interventions: Drug: MB09 (denosumab biosimilar); Drug: EU-Prolia; Dietary Supplement: Elemental Calcium; Dietary Supplement: Vitamin D Sponsor: mAbxience S.A Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials